Tizanidine Hydrochloride Capsule
Product Images NDC 71335-2872

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 71335-2872). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352872)

Label (Lbl713352872)
The text contains information about TiZANidine Hydrochloride capsules. Each capsule contains 6.87 mg Tizanidine Hydrochloride, USP and 6 mg Tizanidine base. It mentions that it may cause drowsiness and should be stored at a temperature range of 20° to 25° C. The medication should be kept out of reach of children and dispensed in a tight, light-resistant container. The text also includes details about the manufacturer and repackager of the capsules.*
FDA Label Image

"image Description" (Tizanidine Hydrochloride Capsules Figure 1)

FDA Label Image

"image Description" (Tizanidine Hydrochloride Capsules Figure 2)

"image Description" (Tizanidine Hydrochloride Capsules Figure 2)
This text provides information regarding dosages of tizanidine (16 mg and 8 mg) and indicates the improvement in Ashworth Score over time post-dose. It appears to be a chart showing the impact of tizanidine on muscle spasticity.*
FDA Label Image

"image Description" (Tizanidine Hydrochloride Capsules Figure 3)

"image Description" (Tizanidine Hydrochloride Capsules Figure 3)
This text provides information about a medication called Tizanidine and mentions the mean dose of 28.8 milligrams. It also refers to the improvement in the Ashworth Score, which may indicate its effect on muscle spasticity. Additionally, it appears to mention different study time points such as the end of the titration period, end of the maintenance phase, and the endpoint observed at week 7 or using the Last Observation Carried Forward method.*
FDA Label Image

"image Description" (Tizanidine Hydrochloride Capsules Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.